Afatinib (BIBW2992)

Catalog No.S1011

Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

Price Stock Quantity  
USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Afatinib (BIBW2992) Chemical Structure

Afatinib (BIBW2992) Chemical Structure
Molecular Weight: 485.94

Validation & Quality Control

Cited by 35 publications:

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

EGFR Inhibitors with Unique Features

  • Selective EGFR Inhibitor

    Erlotinib HCl (OSI-744) EGFR-selective, IC50=2 nM.

  • FDA-approved EGFR Inhibitor

    Lapatinib Approved by FDA for breast cancer.

  • Newest EGFR Inhibitor

    CO-1686 (AVL-301) Irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

  • Classic EGFR Inhibitor

    WZ4002 Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Product Information

  • Compare EGFR Inhibitors
    Compare EGFR Products
  • Research Area
  • Inhibition Profile
  • Afatinib (BIBW2992) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Targets EGFR (L858R) [1]
(Cell-free assay)
EGFR (wt) [1]
(Cell-free assay)
EGFR (L858R/T790M) [1]
(Cell-free assay)
HER2 [1]
(Cell-free assay)
IC50 0.4 nM 0.5 nM 10 nM 14 nM
In vitro BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HDLM-2MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPtfXpKSzVyPUCuNFA2PzJizszNNHzQ[5JUSU6JRWK=
KASUMI-1MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwMEC5NVEh|ryPM4Ozc3NCVkeHUh?=
HCC2218MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M363VWlEPTB;MD6wNFk5PyEQvF2=MmPTV2FPT0WU
KARPAS-45MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjBZZFKSzVyPUCuNFE3PzFizszNNUfJN5oxW0GQR1XS
HSC-4MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NID3PJZKSzVyPUCuNFE4PDhizszNM3y3Z3NCVkeHUh?=
CHL-1NYG0NlA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTBwMEG4N|kh|ryPMVzTRW5ITVJ?
KY821M2exe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULXW3JFUUN3ME2wMlAzODZizszNNWLQ[olVW0GQR1XS
NCI-N87MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\xTWM2OD1yLkCyO|c{KM7:TR?=MVXTRW5ITVJ?
DOKM1TtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIqwUpZKSzVyPUCuNFMyQTRizszNM4HicHNCVkeHUh?=
DSH1NYPkTYd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnQVlFKSzVyPUCuNFM{OTRizszNMYDTRW5ITVJ?
MDA-MB-175-VIINISxSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnu4TWM2OD1yLkCzOFE3KM7:TR?=MnT5V2FPT0WU
NCI-H2170M{LOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HzeGlEPTB;MD6wN|czQCEQvF2=M3LPbXNCVkeHUh?=
BT-474NF;Sb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXGc|BKSzVyPUCuNFQ6QDZizszNMX\TRW5ITVJ?
EFO-27MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTBwMEWxPFIh|ryPNGjXNmVUSU6JRWK=
NCI-H720NFHqRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTBwMEWzNlUh|ryPNXjmbpVWW0GQR1XS
PC-14MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TKbmlEPTB;MD6wOVY3QCEQvF2=NHXp[WNUSU6JRWK=
EC-GI-10NVzjPWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jiemlEPTB;MD6wOVkyOiEQvF2=MUfTRW5ITVJ?
KYSE-450Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M160WWlEPTB;MD6wOVk4QCEQvF2=M1fvdXNCVkeHUh?=
BPH-1M2LMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWH3enRLUUN3ME2wMlA2QTh6IN88US=>M2DGfHNCVkeHUh?=
NCI-H292Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\5WVZEUUN3ME2wMlA3ODlizszNNF7GenpUSU6JRWK=
H9NY\E[lE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\vTWM2OD1yLkC3NVMzKM7:TR?=MV\TRW5ITVJ?
NCI-H526NYPYc3hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;vdGlEPTB;MD6wO|gzOyEQvF2=MU\TRW5ITVJ?
NCI-H1623MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\WTWM2OD1yLkC4NFI2KM7:TR?=MWPTRW5ITVJ?
KYSE-140MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3sTWM2OD1yLkC4N|Mh|ryPNHHVUppUSU6JRWK=
Ca9-22MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTBwMEizOVMh|ryPMoPGV2FPT0WU
AU565NXHGOJB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofUTWM2OD1yLkC4OVA1KM7:TR?=NIXBXFBUSU6JRWK=
ZR-75-30MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LSRWlEPTB;MD6wPVU1PSEQvF2=NFr1V4VUSU6JRWK=
NCI-H1770NIr4W|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTBwMUCyPEDPxE1?MWfTRW5ITVJ?
LB2241-RCCMnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnW[WZKSzVyPUCuNVA5QDRizszNNXPReFFoW0GQR1XS
CAL-39M1jxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1i2TmlEPTB;MD6xNVc6OiEQvF2=M3PkRXNCVkeHUh?=
UACC-893NELmfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHjOWxXUUN3ME2wMlEyQDh3IN88US=>NVT1SXByW0GQR1XS
LU-65NG\nS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPTXZVKSzVyPUCuNVI3OzNizszNMoO1V2FPT0WU
HNMmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jFTGlEPTB;MD6xN|A4PyEQvF2=M2f5fXNCVkeHUh?=
TI-73MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTBwMUS3NVUh|ryPMV;TRW5ITVJ?
KU812NHKwVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjKOlBHUUN3ME2wMlE2PDV4IN88US=>MoXxV2FPT0WU
SW13M{Ptd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLD[I1KSzVyPUCuNVYzOTZizszNNHfkd3pUSU6JRWK=
BB30-HNCMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPaTWM2OD1yLkG2OVc3KM7:TR?=MVTTRW5ITVJ?
HSC-2NYLnfXg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rweGlEPTB;MD6xOlg{PyEQvF2=NXX6dY9IW0GQR1XS
BV-173M2XMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkL4TWM2OD1yLkG3OVk3KM7:TR?=M3jxdnNCVkeHUh?=
CAL-27NH21Z|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTBwMUe2N|Yh|ryPMoLXV2FPT0WU
SBC-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\0XphKSzVyPUCuNVg6PTlizszNM17JT3NCVkeHUh?=
CAL-33M1rGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDZTWM2OD1yLkKwNVg1KM7:TR?=MV;TRW5ITVJ?
NCI-H209NH\adYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\kTWM2OD1yLkKwOFYh|ryPNWPCNIhCW0GQR1XS
COR-L105NXfNcIhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2f5TWlEPTB;MD6yNVA5PCEQvF2=NWr1ZY1XW0GQR1XS
HSC-3MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1uyXGlEPTB;MD6yNVE6QCEQvF2=MUDTRW5ITVJ?
NCI-H69MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVXCSWJ{UUN3ME2wMlIyPDVzIN88US=>NEXQdnJUSU6JRWK=
MOLT-13NIj5[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLkd5piUUN3ME2wMlI{QTd3IN88US=>MV3TRW5ITVJ?
ML-2MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHHTWM2OD1yLkK0PFAzKM7:TR?=M3TxU3NCVkeHUh?=
IGROV-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PjTmlEPTB;MD6yOVk2OiEQvF2=MVzTRW5ITVJ?
TK10M3HESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2[4TWlEPTB;MD6yOlc{QCEQvF2=M2KxTHNCVkeHUh?=
EoL-1-cellNXr1TYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTBwMk[4PVIh|ryPNUPENmRiW0GQR1XS
HO-1-N-1NVLWRVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH33cWNKSzVyPUCuNlc5PTNizszNM3HI[nNCVkeHUh?=
BHYMoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;LR2xKSzVyPUCuNlg3PTVizszNM3vRUXNCVkeHUh?=
LU-139M3Lydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PiV2lEPTB;MD6zNFUyKM7:TR?=MYjTRW5ITVJ?
23132-87NYHwcGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFe2bWNKSzVyPUCuN|E6OjNizszNNXy3fIlJW0GQR1XS
ACHNMlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DEXWlEPTB;MD6zNVk6PCEQvF2=M1:0ZXNCVkeHUh?=
DoTc2-4510MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjDdVR3UUN3ME2wMlMzOjF7IN88US=>Ml23V2FPT0WU
BB65-RCCMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPJU|RKSzVyPUCuN|Q2QTNizszNMkS3V2FPT0WU
HLEMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTBwM{WwOFYh|ryPMYTTRW5ITVJ?
HCC1419MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3q5fWlEPTB;MD6zOlQxQCEQvF2=M4nB[HNCVkeHUh?=
A388NX;QVHd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHU[2xCUUN3ME2wMlM3QDV5IN88US=>MXLTRW5ITVJ?
NUGC-3M3P1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnVTWM2OD1yLkO4N|c{KM7:TR?=M3fMfHNCVkeHUh?=
KYSE-180MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXPU2lKSzVyPUCuN|kxQDlizszNMX;TRW5ITVJ?
TE-6NUTDe2FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;G[2lEPTB;MD60NFI1PiEQvF2=MV3TRW5ITVJ?
A498MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUiwPIg3UUN3ME2wMlQxPjd2IN88US=>MYDTRW5ITVJ?
NCI-H1648NUC2cmZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIWxZ|lKSzVyPUCuOFQyQDJizszNM1nqWHNCVkeHUh?=
DU-145MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTBwNES4N|Mh|ryPMoP4V2FPT0WU
CW-2NHHnTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jLUGlEPTB;MD60OlkyPCEQvF2=MUjTRW5ITVJ?
A431NGTVOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInTNnBKSzVyPUCuOFgzOzNizszNM{n0UXNCVkeHUh?=
SASNF\3U2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTBwNEizPVgh|ryPNIjsS29USU6JRWK=
NCI-H2126NVH6UIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fGXGlEPTB;MD61NVkzPiEQvF2=Mn7IV2FPT0WU
NCI-H358M1XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTBwNUOyNUDPxE1?NHfVU|hUSU6JRWK=
FADUNIHwfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TERWlEPTB;MD61OFQxPCEQvF2=NHvi[3VUSU6JRWK=
ACNM1HTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwNUWwPVQh|ryPNVy2UYRIW0GQR1XS
HCC70M4HXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHtdlNKSzVyPUCuOVc3PjFizszNM3\XdnNCVkeHUh?=
NCI-H1838MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfrVIFTUUN3ME2wMlYxOjl7IN88US=>M{fabXNCVkeHUh?=
CAL-54MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M171VmlEPTB;MD62NVYzOSEQvF2=NEiw[ItUSU6JRWK=
NCI-H1975NYHOPFlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPa[mRlUUN3ME2wMlYyPzJ6IN88US=>MmG5V2FPT0WU
COR-L88NUL5OHZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUX0NHhjUUN3ME2wMlY1OTF|IN88US=>MULTRW5ITVJ?
CTV-1M2HBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DmRmlEPTB;MD62OFM6OiEQvF2=MXnTRW5ITVJ?
EW-18NF7R[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXsTWM2OD1yLk[4Olk5KM7:TR?=NILhNnpUSU6JRWK=
HCC1806MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwNkm2OlYh|ryPMYHTRW5ITVJ?
HuP-T4MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TGS2lEPTB;MD62PVc3KM7:TR?=M4C3fXNCVkeHUh?=
MDA-MB-361MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnraTWM2OD1yLkeyOlYzKM7:TR?=MU\TRW5ITVJ?
NCI-H1573MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTBwN{O2N{DPxE1?MlzXV2FPT0WU
KU-19-19NYPtVpRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2P2ZmlEPTB;MD63O|Q3PCEQvF2=M4TwUXNCVkeHUh?=
COLO-678NEfxXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTBwOEC4N|Qh|ryPM3jzeXNCVkeHUh?=
C-33-ANYS1Zm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{P4R2lEPTB;MD64NVI6PyEQvF2=NHflbZVUSU6JRWK=
Calu-3M3OzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTBwOEG0N|Qh|ryPNIXiblJUSU6JRWK=
AGSNIrjZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:5VG9KSzVyPUCuPFM3PDhizszNM3noc3NCVkeHUh?=
SCC-25NUHHZo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWD0cYx3UUN3ME2wMlg1OTdzIN88US=>MoLLV2FPT0WU
JVM-2MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTBwOEiyPVkh|ryPM2DPOnNCVkeHUh?=
HCE-TNG\Kd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI[5cINKSzVyPUCuPFg1OjhizszNMnrBV2FPT0WU
ES4NUnsTVhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTBwOUe4N|Yh|ryPMWTTRW5ITVJ?
EKVXNVLRPHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnnW49KSzVyPUGuNFExPjRizszNNXrLXHZRW0GQR1XS
D-542MGNVnLO2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TzdWlEPTB;MT6wNVA3PCEQvF2=Mn;uV2FPT0WU
SW1116MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDmbnBOUUN3ME2xMlAyOjh5IN88US=>NXLqSGdJW0GQR1XS
5637MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjVTWM2OD1zLkCxOVEh|ryPNWrJdIZjW0GQR1XS
HT-1376NFezdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;vTWM2OD1zLkCxOVE{KM7:TR?=M17pO3NCVkeHUh?=
NB69NXHtZVhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\0TWM2OD1zLkCyPVQ2KM7:TR?=NYfsN2FrW0GQR1XS
YKG-1NEXmc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonoTWM2OD1zLkC1OFE6KM7:TR?=Mom2V2FPT0WU
EW-3NWrEWlUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7zb4xOUUN3ME2xMlA4QDh|IN88US=>NX3ZbpJEW0GQR1XS
GCIYNH7rPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rabGlEPTB;MT6wPFExPCEQvF2=M4K4cHNCVkeHUh?=
SK-MES-1NXvX[JN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{SxbWlEPTB;MT6xNVQ5PyEQvF2=MUfTRW5ITVJ?
PANC-08-13NInHXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;KU|NEUUN3ME2xMlE3PDF4IN88US=>MXvTRW5ITVJ?
SK-NEP-1M3fGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4D1e2lEPTB;MT6xO|UyOyEQvF2=NHfEZZFUSU6JRWK=
SW954M3jaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTFwMkCyNVQh|ryPMV;TRW5ITVJ?
NCI-SNU-5NXyzSIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTFwMkO5JO69VQ>?M{ftVnNCVkeHUh?=
SW48MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHmbnA3UUN3ME2xMlI2PDN{IN88US=>MUnTRW5ITVJ?
HT-3MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjOPHlIUUN3ME2xMlI5PzV|IN88US=>NV;CSXZ1W0GQR1XS
ETK-1MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHe5UnNKSzVyPUGuN|c1PTZizszNMo\VV2FPT0WU
SCC-15M1\3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nHTGlEPTB;MT6zPVQ2OSEQvF2=NV3QXZNiW0GQR1XS
DU-4475MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPIcYpRUUN3ME2xMlQxOTJzIN88US=>MmO4V2FPT0WU
NB5MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\uTmlEPTB;MT60NVMyPyEQvF2=NH7rbJNUSU6JRWK=
CFPAC-1NETwcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\aVlBKSzVyPUGuOFI1QTNizszNM1[xNXNCVkeHUh?=
NCI-H630Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPQXIFDUUN3ME2xMlQ2PTh{IN88US=>M2TCe3NCVkeHUh?=
NCI-H82MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HFSGlEPTB;MT61OFAxPiEQvF2=NIXkWnpUSU6JRWK=
ECC10M{jle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLvW5hVUUN3ME2xMlU2OzZ7IN88US=>NGnrRmRUSU6JRWK=
K5M2PHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWGyXJF{UUN3ME2xMlU5OzV5IN88US=>NUWwOVBLW0GQR1XS
ME-180MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDYTWM2OD1zLk[xNFk3KM7:TR?=NUjxco5iW0GQR1XS
KYSE-410NFPCOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\XWWxkUUN3ME2xMlY2Pjd{IN88US=>NEXIUW9USU6JRWK=
G-401MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHacZhGUUN3ME2xMlY4PDF|IN88US=>MoW4V2FPT0WU
TGBC24TKBNUPqcZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDwelF{UUN3ME2xMlY5OjNizszNNX;tNppuW0GQR1XS
Detroit562NVftTWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;BTWM2OD1zLkewNVUzKM7:TR?=NFiwcVFUSU6JRWK=
OE19MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFwN{G1NVIh|ryPNYrM[JBWW0GQR1XS
CAKI-1NWCxXWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTFwN{iyNVEh|ryPMUTTRW5ITVJ?
TE-12MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkm5TWM2OD1zLkiwOFE1KM7:TR?=NEHYOIZUSU6JRWK=
NCI-H1666MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\6TWVsUUN3ME2xMlgxQTR6IN88US=>M1P5ZnNCVkeHUh?=
TE-1M4DLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDsVJU1UUN3ME2xMlgyPDd3IN88US=>NWDnOlNUW0GQR1XS
CAL-12TMlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vx[WlEPTB;MT64PFk1PSEQvF2=MmLTV2FPT0WU
TE-8NF34epZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzs[ZlKSzVyPUGuPVE{PzdizszNNYLHXJI3W0GQR1XS
KYSE-270MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTJwMEK3N|Ih|ryPM3L4V3NCVkeHUh?=
GMS-10NIO4bFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJwMEO1NVch|ryPMUfTRW5ITVJ?
A2780NGLGWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJwME[yPVQh|ryPMYnTRW5ITVJ?
OMC-1NY\OVG02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLaT5JtUUN3ME2yMlA5OTZ7IN88US=>NF;aeoVUSU6JRWK=
LoVoM{XyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nYcGlEPTB;Mj6xNFc6PyEQvF2=NHrXbmpUSU6JRWK=
PANC-03-27NFrkb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXm1UVdlUUN3ME2yMlE3PjNzIN88US=>MmnOV2FPT0WU
MDA-MB-157MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7UTWM2OD1{LkKxPFI5KM7:TR?=NYS4VXZLW0GQR1XS
CaR-1NXHpPVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2[4NmlEPTB;Mj6yPFI5OSEQvF2=M173R3NCVkeHUh?=
769-PMmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTJwMkmwN|ch|ryPNHTGNGFUSU6JRWK=
NB7NYPRSYU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTJwMkm2O|Yh|ryPNILWZ4VUSU6JRWK=
MKN7M4\uTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTJwM{WzN|Uh|ryPM3XQ[HNCVkeHUh?=
NCI-H1048MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fxSGlEPTB;Mj60PVE2QCEQvF2=NYDTR5FDW0GQR1XS
RCM-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LWd2lEPTB;Mj61Nlk{QCEQvF2=M3HYOXNCVkeHUh?=
HT55Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvBdllKSzVyPUKuOVc{QCEQvF2=NX72bnRwW0GQR1XS
HCC1569MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXy4bWZWUUN3ME2yMlU5Ojl5IN88US=>MnHqV2FPT0WU
LXF-289MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTJwNkO1OlUh|ryPNX:wO3BsW0GQR1XS
OVCAR-3NITqR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{X5dGlEPTB;Mj62O|E3PyEQvF2=MWDTRW5ITVJ?
TE-10NFnvOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETyR2hKSzVyPUKuOlgxPzhizszNNF7sb|dUSU6JRWK=
SNU-C2BNYDK[lRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nib2lEPTB;Mj62PFYyPiEQvF2=MU\TRW5ITVJ?
LB1047-RCCMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PrWmlEPTB;Mj63OFg5QCEQvF2=NHK2eI5USU6JRWK=
SN12CMnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTJwOUG5OlQh|ryPMofsV2FPT0WU
786-0NIDBRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTNwME[0NFgh|ryPMX\TRW5ITVJ?
HT-29MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrBTWM2OD1|LkC3N|A6KM7:TR?=MlLwV2FPT0WU
RPMI-7951M{f0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTNwMEe1PUDPxE1?NYnvenZzW0GQR1XS
NBsusSRNW\GN3N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zme2lEPTB;Mz6xPFI2PCEQvF2=MnrEV2FPT0WU
NKM-1MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnpfllXUUN3ME2zMlE5PzR2IN88US=>MXfTRW5ITVJ?
Capan-2MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInZe3ZKSzVyPUOuOFY5PzVizszNNFz1d5VUSU6JRWK=
MKN1MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TKU2lEPTB;Mz60O|ExQCEQvF2=MYXTRW5ITVJ?
OAW-42M4LHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIj6e|JKSzVyPUOuOVAxOjZizszNNVzI[GViW0GQR1XS
SKG-IIIaMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XhWmlEPTB;Mz61NlI{PyEQvF2=MVnTRW5ITVJ?
no-11MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7JeHpKSzVyPUOuOVM2PjRizszNM4DKPHNCVkeHUh?=
NYMkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzRRYs3UUN3ME2zMlU{PjV3IN88US=>MkjIV2FPT0WU
HEC-1M4nxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jBT2lEPTB;Mz61PFk2KM7:TR?=Mm[wV2FPT0WU
NCI-H441NIGydJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPxcHh[UUN3ME2zMlU6QDRzIN88US=>MkXOV2FPT0WU
NCI-H2009MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFiyRoZKSzVyPUOuOlEzOTZizszNNXfy[mR5W0GQR1XS
T47DMmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTNwNkKyNVch|ryPMWnTRW5ITVJ?
SNU-449M{DZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXtTWM2OD1|Lk[1PFI3KM7:TR?=M1S1fXNCVkeHUh?=
NCI-SNU-1MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTNwNkm3N|Uh|ryPNXTOeGoxW0GQR1XS
BT-20M3G2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTNwNkm3PVUh|ryPNH;tOmZUSU6JRWK=
LS-123NUW2fox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjHRohKSzVyPUOuO|QzQDRizszNMUjTRW5ITVJ?
8305CNVLhfYNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fIV2lEPTB;Mz63OVkyOSEQvF2=NFv2d2JUSU6JRWK=
OCUB-MNVPKcXI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTNwN{[xPFch|ryPMoH2V2FPT0WU
KOSC-2MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;ITWM2OD1|LkizOFUyKM7:TR?=NVK3cmtSW0GQR1XS
NCI-H1693MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTNwOESxPFEh|ryPNIrhbGhUSU6JRWK=
TE-9Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTNwOESzPFIh|ryPM3\YVHNCVkeHUh?=
MV-4-11NFzoR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TnSWlEPTB;Mz64O|k6PCEQvF2=M1fEOXNCVkeHUh?=
GAMGNIX6XHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfiTWlkUUN3ME2zMlkyOzF2IN88US=>Ml\SV2FPT0WU
KNS-62M3nZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTNwOUS3N|Eh|ryPM2q3b3NCVkeHUh?=
MC116NU\Wb|BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTNwOUW0PFkh|ryPMlLqV2FPT0WU
647-VMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWLUXYFsUUN3ME2zMlk5PDV{IN88US=>M{nKdXNCVkeHUh?=
U-87-MGM4K0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rpSWlEPTB;ND6xNFQ5OSEQvF2=NGjvR5ZUSU6JRWK=
RPMI-8226NELFSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LBb2lEPTB;ND6xNVY{OSEQvF2=NWWxdXdnW0GQR1XS
SW1417MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4m5N2lEPTB;ND6xNlE1PyEQvF2=Mn\IV2FPT0WU
LAMA-84NGHj[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\0TWM2OD12LkG3NFIh|ryPNH63WFNUSU6JRWK=
LS-513MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TZXGlEPTB;ND6zNVIyPyEQvF2=MX\TRW5ITVJ?
KLEMkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTRwNEC4NVkh|ryPM{D6R3NCVkeHUh?=
HCT-116M3fyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTRwNEGwNFch|ryPMX\TRW5ITVJ?
EPLC-272HNW\aVJRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDv[|NKSzVyPUSuOFE2OzNizszNNX\tWpBbW0GQR1XS
KS-1NV24[llRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTRwNUC4PFkh|ryPMVrTRW5ITVJ?
HT-1197NHT4d3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTRwNUK2Olkh|ryPM2faNXNCVkeHUh?=
LCLC-97TM1MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXHW4JKSzVyPUSuOVM3QDZizszNM2X5cnNCVkeHUh?=
ES5M{PX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTRwOEO3NlMh|ryPMnvtV2FPT0WU
CTB-1NUHKWot[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUW0TI9sUUN3ME20Mlg1QDhizszNNIPiOI1USU6JRWK=
HL-60NWrtWmR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DBVGlEPTB;ND64OlYyOSEQvF2=Mn70V2FPT0WU
VM-CUB-1NVqxRmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTRwOE[4NVkh|ryPNHLCO4NUSU6JRWK=
MEG-01MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjsdmxKSzVyPUSuPVk1ODNizszNM1rJ[HNCVkeHUh?=
KYSE-520M1jnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTVwMkC4N|kh|ryPNV3FdlBmW0GQR1XS
HuO-3N1MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTVwMkSwOFMh|ryPM1zSdHNCVkeHUh?=
SW620M3zhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTVwMkS5OlQh|ryPNXLjWI5ZW0GQR1XS
U031NWXJbHdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTuZ2ZKSzVyPUWuNlU1OjRizszNNWr1fol6W0GQR1XS
TE-5NYnDSZgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TBcWlEPTB;NT60NFg2KM7:TR?=NFjBXWtUSU6JRWK=
NCI-H747NYHTZW05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LDWmlEPTB;NT60NlQ4OiEQvF2=M1TXbnNCVkeHUh?=
MG-63MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fHRmlEPTB;NT60PFc3OiEQvF2=NGDSSoVUSU6JRWK=
HC-1NHTNWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTVwNUG4N|kh|ryPNGL6XGlUSU6JRWK=
HCC2998NXTLd4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrFR3lKSzVyPUWuOVI3OTVizszNNI\GflFUSU6JRWK=
NTERA-S-cl-D1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzpTWM2OD13LkW0OVM4KM7:TR?=NVqzV3I4W0GQR1XS
KINGS-1Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTVwNkC5OFQh|ryPNFu5RopUSU6JRWK=
D-423MGNH7VSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPETWM2OD13Lk[xO|A2KM7:TR?=NH;hbW1USU6JRWK=
SW962Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqyNlRrUUN3ME21MlYzODN{IN88US=>MUXTRW5ITVJ?
LOXIMVIM3HhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3nTlJzUUN3ME21MlY{QDd|IN88US=>NWHUT2FUW0GQR1XS
LS-411NMojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfOT2NKSzVyPUWuO|k1PDFizszNNWDJe4FuW0GQR1XS
NCI-H2291NVrLT|R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfsVodKSzVyPUWuPVg6PDNizszNNH;RPG1USU6JRWK=
A549NEK1[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTjfldxUUN3ME22MlEzPTV|IN88US=>NHntRoZUSU6JRWK=
LS-1034Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTyW4hSUUN3ME22MlIxPzB4IN88US=>MnW1V2FPT0WU
NB14M1O2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LDZWlEPTB;Nj60N|g{PiEQvF2=M2f2R3NCVkeHUh?=
NCI-H1299Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HsXGlEPTB;Nj62N|E4OSEQvF2=NYTweHVzW0GQR1XS
BT-549M4T3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TX[WlEPTB;Nj62Olg5QSEQvF2=M374WHNCVkeHUh?=
J-RT3-T3-5M4L6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTZwOE[5JO69VQ>?M3y5UnNCVkeHUh?=
SW756MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rQT2lEPTB;Nj65NVE4PiEQvF2=MXnTRW5ITVJ?
DJM-1MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLmTWM2OD14LkmyNFEzKM7:TR?=NIjMOWpUSU6JRWK=
GP5dM3rPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTZwOUezPVQh|ryPM4jjWXNCVkeHUh?=
MOLT-4NGLQfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTdwMEKxN|Uh|ryPM4THN3NCVkeHUh?=
NCI-H28M4jnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrEdmxKSzVyPUeuNVY1ODVizszNNXzBdnIzW0GQR1XS
MN-60MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fnS2lEPTB;Nz6yPFA5QSEQvF2=NFixUIFUSU6JRWK=
RMG-IMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnt[XVlUUN3ME23MlM6Ojl4IN88US=>M2[w[HNCVkeHUh?=
COLO-800NIHKTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTdwNEG0OFYh|ryPMYLTRW5ITVJ?
DBM2\XUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTdwNkGwNFUh|ryPNYDqTodpW0GQR1XS
Ca-SkiNHvhZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULyOFJkUUN3ME23MlY1OjV7IN88US=>MXrTRW5ITVJ?
HELM3n0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{CwXGlEPTB;Nz63NVIxOyEQvF2=M3vwbHNCVkeHUh?=
NH-12NUW3RmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPPTWM2OD15LkeyPFA5KM7:TR?=NIjRRmRUSU6JRWK=
LB373-MEL-DMkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTdwN{[3O|Eh|ryPMWfTRW5ITVJ?
SW900M13Lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\TeY1rUUN3ME23MlgzOTJzIN88US=>M2faeXNCVkeHUh?=
JVM-3MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jlbWlEPTB;Nz64PVU6QSEQvF2=MWrTRW5ITVJ?
OAW-28Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M173eGlEPTB;Nz65OFU4QCEQvF2=MVLTRW5ITVJ?
KURAMOCHINFfCNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrKR2lKSzVyPUeuPVQ5OTFizszNNVnFTFZmW0GQR1XS
BE-13MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PhSmlEPTB;Nz65PFEyOiEQvF2=NHL6O5lUSU6JRWK=
VMRC-RCZNFfIenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2S5fGlEPTB;OD6wNVY6PyEQvF2=Mk\WV2FPT0WU
NCI-H727MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRThwMUC0NkDPxE1?NFTkVHNUSU6JRWK=
SW1710M1PPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\KTWM2OD16LkG4OVE2KM7:TR?=MXrTRW5ITVJ?
D-502MGMn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRThwMkmyPFIh|ryPMo\aV2FPT0WU
NCI-H1993NYX1V5YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkT1TWM2OD16LkOzOlMyKM7:TR?=M3\LPXNCVkeHUh?=
SCC-4M17ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRThwNESwOVkh|ryPMofGV2FPT0WU
HAL-01NH;2b3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzuTZVIUUN3ME24MlUyQTFizszNMmDPV2FPT0WU
GT3TKBNHvCb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\WNJFDUUN3ME24MlY4QTZ2IN88US=>M1q3R3NCVkeHUh?=
SK-OV-3MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DBWGlEPTB;OD63NVMzQSEQvF2=M2jSPXNCVkeHUh?=
COLO-829NHnlTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRThwOEC5O|Yh|ryPM{jXNnNCVkeHUh?=
OCI-AML2NYfHW|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnyblB1UUN3ME24Mlk2PDhzIN88US=>NUH0R3N[W0GQR1XS
OS-RC-2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTlwMEKxPUDPxE1?NWT6[JVCW0GQR1XS
BFTC-909MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzPTWM2OD17LkC2O|k6KM7:TR?=NGG2dIxUSU6JRWK=
EW-11NXSxboN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHew[nNKSzVyPUmuNVc3PTNizszNNFnHNHlUSU6JRWK=
HCE-4NF6w[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTZSIdKSzVyPUmuNlE2PThizszNMVHTRW5ITVJ?
BALL-1NGLIOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTwTWM2OD17LkKxPVA4KM7:TR?=NXjnO5h1W0GQR1XS
SF539MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEeyV3dKSzVyPUmuNlM2PjJizszNMVvTRW5ITVJ?
CAMA-1M3\IU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7MTWM2OD17LkK4NVI5KM7:TR?=MYTTRW5ITVJ?
C32MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HET2lEPTB;OT6zN|A3PCEQvF2=MVPTRW5ITVJ?
NCI-H1703MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7lVGlKSzVyPUmuN|Q{PzVizszNNEDxeVdUSU6JRWK=
NCI-H1650NE\nfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PCZ2lEPTB;OT62NFk1PiEQvF2=MXzTRW5ITVJ?
NCI-H1563NXzwXY5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUH4TFN3UUN3ME25Mlc3ODNzIN88US=>NUOySVVEW0GQR1XS
CAL-85-1NGPhO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPBTWM2OD17Lki3N|g{KM7:TR?=NHXzdGZUSU6JRWK=
UM-UC-3MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnO0TWM2OD17Lkm1NFMh|ryPMorXV2FPT0WU
BxPC-3MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTFyLkC5O|Ih|ryPMmDlV2FPT0WU
MHH-PREB-1NYPzcGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\FbpkzUUN3ME2xNE4yQTl7IN88US=>NIrXO|dUSU6JRWK=
DELNGjUWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTFyLkO5OFYh|ryPMoL6V2FPT0WU
HuCCT1M4LuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;0WohMUUN3ME2xNE43ODN|IN88US=>NH;CdmNUSU6JRWK=
OVCAR-4NYLtWWRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vDcWlEPTB;MUCuPFg{PSEQvF2=NX6xNGR3W0GQR1XS
CAL-72NHfoeIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorzTWM2OD1zMD65N|kyKM7:TR?=M2TTTXNCVkeHUh?=
HCC1954MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTFzLkC3OVQh|ryPNGX0[|NUSU6JRWK=
EFO-21NF7VVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDaN5l4UUN3ME2xNU4yODR3IN88US=>MU\TRW5ITVJ?
FTC-133M4O0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHKdW5wUUN3ME2xNU4yPDB5IN88US=>NH;Kc3lUSU6JRWK=
SK-MEL-24Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4r3W2lEPTB;MUGuNlM3PiEQvF2=MnixV2FPT0WU
UACC-62NETZ[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XZfGlEPTB;MUGuNlM3QCEQvF2=NH2yOYVUSU6JRWK=
NCI-H650MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HLVmlEPTB;MUGuNlQyQCEQvF2=NHjPXFVUSU6JRWK=
ALL-PONIfnTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTFzLkK1NVIh|ryPNGnnXJJUSU6JRWK=
T84MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjVTWM2OD1zMT6zPVA4KM7:TR?=NH74TmpUSU6JRWK=
IST-MEL1NIm5TnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\TTWM2OD1zMT60OVU6KM7:TR?=MkSyV2FPT0WU
SW626M33se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTFzLkW3OVUh|ryPNFnJTI9USU6JRWK=
RPMI-2650M{faW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fGNWlEPTB;MUGuOVg5PSEQvF2=M4ftTnNCVkeHUh?=
MC-IXCMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHxTWM2OD1zMT62O|I5KM7:TR?=NWOwfVZJW0GQR1XS
HOP-62NWHWNVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17BUGlEPTB;MUGuOlc3PCEQvF2=MVrTRW5ITVJ?
NOS-1NV7hUZZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\VTWM2OD1zMT63NVA6KM7:TR?=MnnFV2FPT0WU
SW1573NYHsOoFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;vS2lEPTB;MUGuO|I6PSEQvF2=Mn3DV2FPT0WU
WM-115MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2C3[WlEPTB;MUGuO|U5QCEQvF2=NUPPS2lHW0GQR1XS
HuO9MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDrdpFKSzVyPUGxMlg4PzRizszNMorpV2FPT0WU
YAPCNUn6dmtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTFzLkmyOVkh|ryPMlT3V2FPT0WU
MDA-MB-453NITOTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFizRlhKSzVyPUGxMlk2OTVizszNNH7i[VFUSU6JRWK=
NCI-H596M{PF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDJTWM2OD1zMj6wN|Y6KM7:TR?=M2LN[nNCVkeHUh?=
A172M{Phfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHDRY1KUUN3ME2xNk4xPzl6IN88US=>NVXUXpVqW0GQR1XS
RS4-11MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYK0TVVDUUN3ME2xNk4yPzJ3IN88US=>M1e0N3NCVkeHUh?=
HCC1937MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTF{Lke1OlQh|ryPMlTFV2FPT0WU
SW837Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTF{LkmwNlgh|ryPNGD3c3dUSU6JRWK=
NMC-G1MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XS[WlEPTB;MUKuPVI{PCEQvF2=Mn7WV2FPT0WU
PFSK-1NFzBcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnxNGlKSzVyPUGzMlA3KM7:TR?=M4LVOXNCVkeHUh?=
DBTRG-05MGNITYc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnniTWM2OD1zMz6wOlMzKM7:TR?=M4XsOXNCVkeHUh?=
SK-UT-1M3TDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlv2TWM2OD1zMz6xNFg{KM7:TR?=NGX5SlJUSU6JRWK=
OVCAR-5MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG5bYVKSzVyPUGzMlE2QTNizszNNVuxU|lMW0GQR1XS
8505CMlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jvSGlEPTB;MUOuNlA3PyEQvF2=MVzTRW5ITVJ?
SK-MEL-1NXrTNJFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvrTWM2OD1zMz63NVM2KM7:TR?=MXTTRW5ITVJ?
LK-2NI\OVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn2zTWM2OD1zMz63OlM6KM7:TR?=Mn7qV2FPT0WU
OE33NE\S[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTF|Lke4OkDPxE1?M{TVcXNCVkeHUh?=
Ramos-2G6-4C10NXnZS3B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTyXnpKSzVyPUG0MlAzODJizszNM1LFPHNCVkeHUh?=
EW-13MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTF2LkCzOVIh|ryPNHjEPVFUSU6JRWK=
NCI-H1793NFSzUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\1dmQxUUN3ME2xOE4zODh5IN88US=>M3m5VnNCVkeHUh?=
BHT-101NGTvVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLKT5djUUN3ME2xOE4zPDFizszNMl3aV2FPT0WU
RKOMkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTF2LkWwO|Uh|ryPNH;wW2VUSU6JRWK=
NEC8MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTF2LkW0O|Ih|ryPNVHIOI5SW0GQR1XS
PANC-10-05MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7pTWM2OD1zND62NlQ4KM7:TR?=MXTTRW5ITVJ?
NCI-H2030M4LoWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPMTWM2OD1zND62OFQ5KM7:TR?=MkXnV2FPT0WU
C2BBe1M{LBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonPTWM2OD1zND63OlQh|ryPNGj3dXVUSU6JRWK=
EM-2NFjDbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLvTohZUUN3ME2xOE45PTd4IN88US=>MXnTRW5ITVJ?
HCC1395NYS0e242T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnuSWh{UUN3ME2xOE46OzN6IN88US=>NHT2e|RUSU6JRWK=
A2058M{fIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLXTWM2OD1zNT6wOFA6KM7:TR?=NFnoc4pUSU6JRWK=
SW1463M{ewe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTF3LkC0PFUh|ryPNILocoZUSU6JRWK=
J82NEez[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LtfmlEPTB;MUWuNFU4KM7:TR?=MXHTRW5ITVJ?
CAL-120NGjXWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MluzTWM2OD1zNT6xOFQ4KM7:TR?=NWn3bYo1W0GQR1XS
COLO-824M1nFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TibmlEPTB;MUWuNVU4QSEQvF2=Mlm0V2FPT0WU
LNCaP-Clone-FGCM2Docmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nE[mlEPTB;MUWuOFI1QCEQvF2=MkniV2FPT0WU
CP66-MELNIn2bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXQTWM2OD1zNT60Olg5KM7:TR?=M2jPSHNCVkeHUh?=
OC-314NFv2WGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2D0bmlEPTB;MUWuOFcyPCEQvF2=MWTTRW5ITVJ?
OVCAR-8Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjuNGxKSzVyPUG1Mlg5PjFizszNNXHENItoW0GQR1XS
MFE-280NWO1W4s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIexNnNKSzVyPUG2MlA1QDhizszNNEiwTIlUSU6JRWK=
MHH-NB-11MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPWdJJLUUN3ME2xOk4xQDN7IN88US=>MX7TRW5ITVJ?
SW1990MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2iz[2lEPTB;MU[uNVc2PSEQvF2=NHfv[nFUSU6JRWK=
U-266NXK2OFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HiOWlEPTB;MU[uNlI6QSEQvF2=M4XBOnNCVkeHUh?=
MFM-223MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjHdG9xUUN3ME2xOk4{QTZ3IN88US=>NFvaeYxUSU6JRWK=
L-363NXi5eVlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHvfW5FUUN3ME2xOk41PTd5IN88US=>NYX3S2RiW0GQR1XS
MCF7NVr0N49DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPZT3BbUUN3ME2xOk41PzJ|IN88US=>M2HKOnNCVkeHUh?=
SK-MEL-3NGT4WYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TLWmlEPTB;MU[uOFc5PyEQvF2=M1\MZ3NCVkeHUh?=
HHNYH2NYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjFTWM2OD1zNj61NVYzKM7:TR?=NHzNSZBUSU6JRWK=
no-10MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3i0UmlEPTB;MU[uOlM1OyEQvF2=MmrKV2FPT0WU
HuP-T3NHXtboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PuT2lEPTB;MU[uOlU4PiEQvF2=NGDMSmlUSU6JRWK=
QIMR-WILMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF4LkexNFUh|ryPM{O1TXNCVkeHUh?=
NCI-H1092MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrL[GdKSzVyPUG2Mlg{OTZizszNM2rqV3NCVkeHUh?=
MZ2-MELM4HaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTF4Lki0NFMh|ryPNIG0TJlUSU6JRWK=
ES3MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zG[GlEPTB;MU[uPVE{PCEQvF2=NHr5bopUSU6JRWK=
COLO-684M4WwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnSxTWM2OD1zNj65OFc4KM7:TR?=NXjCSGczW0GQR1XS
NCI-H661MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXP2dotsUUN3ME2xOk46Pjl2IN88US=>M3nnb3NCVkeHUh?=
CP50-MEL-BNI\r[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3HVY5KSzVyPUG3MlA{PDNizszNMWHTRW5ITVJ?
NCI-H2405NGG2PW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTF5LkG5O|Qh|ryPMWrTRW5ITVJ?
U-2-OSMorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnYTWM2OD1zNz61N|A4KM7:TR?=M{PkbHNCVkeHUh?=
RERF-LC-MSMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH7KdGtKSzVyPUG3MlU2ODhizszNNXPrUGFkW0GQR1XS
NCI-H2342NFnxb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF5LkW1O{DPxE1?MXLTRW5ITVJ?
ES8MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEK0WJRKSzVyPUG3MlYxQDdizszNNVO2W5RkW0GQR1XS
MOLT-16NFHrVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFH4NZZKSzVyPUG3Mlg6OzRizszNM4nvbnNCVkeHUh?=
RH-18Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH30NFhKSzVyPUG4MlAxOzVizszNM1izdnNCVkeHUh?=
D-283MEDNG\PZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmT0TWM2OD1zOD6wNFg5KM7:TR?=NU\LOXNuW0GQR1XS
RCC10RGBMlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjme3VQUUN3ME2xPE4xPTV7IN88US=>NVjhR|dSW0GQR1XS
NCI-H1437MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTF6LkG2OFEh|ryPNELXSFhUSU6JRWK=
SW982NVzYeoxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vXU2lEPTB;MUiuNlY4OSEQvF2=MXvTRW5ITVJ?
IST-MES1NY\4XGs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTF6LkS0Nlgh|ryPM2HhVnNCVkeHUh?=
A704M3LsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmexTWM2OD1zOD60O|U{KM7:TR?=MULTRW5ITVJ?
ESS-1NIn2Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjGe2J7UUN3ME2xPE42OjB3IN88US=>MlnQV2FPT0WU
SCHM{DEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHK4OI5KSzVyPUG4MlY1PTZizszNM3fVNXNCVkeHUh?=
COLO-320-HSRNEGwS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTF6Lke0OkDPxE1?NGTTNnZUSU6JRWK=
Mo-TMkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDPTWM2OD1zOD64NlA1KM7:TR?=NI\pWIFUSU6JRWK=
Saos-2NV3WPZV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYi5TItvUUN3ME2xPU4yOTZ{IN88US=>Ml;GV2FPT0WU
SW684M2TjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTF7LkGzNlYh|ryPM3z4XXNCVkeHUh?=
KMOE-2M4HI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTF7LkKyOFIh|ryPNV65T2lTW0GQR1XS
MMAC-SFMljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzsSIE5UUN3ME2xPU4zPjB5IN88US=>NEnzeFFUSU6JRWK=
JARNX\FPYZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fLSGlEPTB;MUmuNlk6KM7:TR?=MVXTRW5ITVJ?
SK-MEL-28NIXuRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{T6XWlEPTB;MUmuN|M3OyEQvF2=MoHKV2FPT0WU
KNS-81-FDNIrCUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rxdmlEPTB;MUmuOVQ3QCEQvF2=MoDCV2FPT0WU
ES7NHr1b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmO1TWM2OD1zOT62NlkzKM7:TR?=MUTTRW5ITVJ?
AsPC-1NWiwOWFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTF7Lk[0O|Eh|ryPMoXOV2FPT0WU
NCI-H1155MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3OcllKSzVyPUG5MlczOzhizszNNFzwe|NUSU6JRWK=
KYSE-510NXHnNVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DsOWlEPTB;MUmuPFc1QCEQvF2=NUDCdlV3W0GQR1XS
ES1M1r2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXQ[nFKSzVyPUG5MlkzOTNizszNNF3t[FNUSU6JRWK=
PC-3M{TmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELVfohKSzVyPUG5Mlk3ODRizszNNVLseYxkW0GQR1XS
GCTNWGwXm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTJyLkOwNlYh|ryPMYDTRW5ITVJ?
KARPAS-299MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTJyLkO0NlIh|ryPNIHxZ5dUSU6JRWK=
DOHH-2MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTJyLkW0OlMh|ryPNYO4SJNtW0GQR1XS
COLO-741MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTJyLk[2JO69VQ>?NG\GfWdUSU6JRWK=
NCI-H1395NI[xc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorqTWM2OD1{MD62Olk4KM7:TR?=MoHVV2FPT0WU
HCC1187NF:xS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXaPXFYUUN3ME2yNE43PzN2IN88US=>MlvGV2FPT0WU
BeckerMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTJyLkeyNFEh|ryPNH3jUFdUSU6JRWK=
LU-134-ANIXpOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LsVGlEPTB;MkGuNVAzPiEQvF2=M1rXSnNCVkeHUh?=
MKN45MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHK2enRKSzVyPUKxMlE2PTFizszNNInFS45USU6JRWK=
LC-2-adMlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TsfGlEPTB;MkGuNlczQSEQvF2=MYrTRW5ITVJ?
EW-24NUKzem9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlr3TWM2OD1{MT6zPVQ2KM7:TR?=NEfPZWpUSU6JRWK=
SK-N-ASNF;FZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rTUmlEPTB;MkGuPFI4PiEQvF2=NIrsWYNUSU6JRWK=
NCI-H2052NXrRRZBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXMcJVmUUN3ME2yNU45QTZ|IN88US=>NHKwUFdUSU6JRWK=
A4-FukMk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTJ{LkG0NVkh|ryPNUD6UYx2W0GQR1XS
NB10MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XrV2lEPTB;MkKuNlM4OSEQvF2=Ml3wV2FPT0WU
CHP-212MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfvbFVKSzVyPUKyMlMzOjJizszNNGOwSHlUSU6JRWK=
KM12MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTJ{LkO1OkDPxE1?NYfkTZRsW0GQR1XS
JEG-3NFToVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofwTWM2OD1{Mj6zO|gh|ryPMoiwV2FPT0WU
LN-405NE\BWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE[2O2tKSzVyPUKyMlU6OTNizszNMl[2V2FPT0WU
HCT-15NW\rV45OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;vOpF5UUN3ME2yNk44PDRzIN88US=>MoLyV2FPT0WU
MLMAMlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTJ{Lke0O{DPxE1?MkPNV2FPT0WU
GI-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYT3Wpd4UUN3ME2yNk44PjV6IN88US=>MV\TRW5ITVJ?
RT-112NW\FdFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfhPXlKSzVyPUKyMlg3OTZizszNNXL0V3BPW0GQR1XS
MPP-89NVr1eWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHm1O4RKSzVyPUKyMlg3PjFizszNMXzTRW5ITVJ?
A3-KAWMlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzZTWM2OD1{Mz6xNFA{KM7:TR?=NFL6UYdUSU6JRWK=
KALS-1MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTJ|LkG0NVQh|ryPMXHTRW5ITVJ?
SF126MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPOTWM2OD1{Mz62PVI1KM7:TR?=MYXTRW5ITVJ?
SiHaMmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PZfWlEPTB;MkOuPVMzPyEQvF2=Mom0V2FPT0WU
MDA-MB-415NUi0fWZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlL0TWM2OD1{Mz65OFk6KM7:TR?=NWTXW5F5W0GQR1XS
DaoyNXvF[GZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJ2LkGyOkDPxE1?M{DIWnNCVkeHUh?=
COR-L23M4\y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJ2LkG3Olch|ryPMXvTRW5ITVJ?
KG-1Mn3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTJ2LkG5Nlgh|ryPNV:xPGpuW0GQR1XS
L-428NXXyNWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXLfoJKSzVyPUK0MlU4QTFizszNNH;LOJlUSU6JRWK=
NCI-H520MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\FVZpLUUN3ME2yOE45QDZzIN88US=>NIr5b4NUSU6JRWK=
COLO-792MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\hN3AzUUN3ME2yOU4zPzN{IN88US=>NWHqV49zW0GQR1XS
NB12MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTJ3LkK5OFch|ryPNWOzZYJsW0GQR1XS
GAKM1TuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\I[lNvUUN3ME2yOU4zQTZ|IN88US=>MW\TRW5ITVJ?
SW780NUHGc|VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLkTWM2OD1{NT6zNlY1KM7:TR?=MkTSV2FPT0WU
GB-1Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\l[ZFmUUN3ME2yOU41ODZ7IN88US=>NYXKblJkW0GQR1XS
P12-ICHIKAWANFT5ZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\mTWM2OD1{NT60O|g2KM7:TR?=NHXjd4ZUSU6JRWK=
NCI-H1651MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT6TWM2OD1{NT61PVch|ryPMnT6V2FPT0WU
KE-37NYjNb2w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJ3LkezNVUh|ryPM1vVXnNCVkeHUh?=
CCRF-CEMMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnHN4JKSzVyPUK1Mlk3PyEQvF2=Mln1V2FPT0WU
SF295NV;mU3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPafJFKSzVyPUK2MlA1OjVizszNNX3CUlZ6W0GQR1XS
G-361M2jOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlP2TWM2OD1{Nj6xNFI4KM7:TR?=M{i4UXNCVkeHUh?=
HOP-92MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHOR2pmUUN3ME2yOk4yOjJ4IN88US=>NYfBdYhTW0GQR1XS
UMC-11MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnUdG5mUUN3ME2yOk41PTF2IN88US=>M2rFRnNCVkeHUh?=
IST-SL1NYrScmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJ4Lk[1PVEh|ryPNUjkUpdyW0GQR1XS
TE-11MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\wTWM2OD1{Nj63O|UzKM7:TR?=MWnTRW5ITVJ?
NCI-H1304MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlq3TWM2OD1{Nj65NVA5KM7:TR?=M4j4OnNCVkeHUh?=
SJSA-1MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXadmtKSzVyPUK3MlAyPzZizszNMVPTRW5ITVJ?
BCPAPNGnmPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJ5LkGzO{DPxE1?M4\ZN3NCVkeHUh?=
HTC-C3NFLneZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jDOGlEPTB;MkeuNlU3OSEQvF2=MoPVV2FPT0WU
EW-16M{TocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rOTGlEPTB;MkeuNlk1PyEQvF2=M2XHfnNCVkeHUh?=
HT-144MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;3SmJKSzVyPUK3MlQxOzJizszNNX:5fVVQW0GQR1XS
MHH-ES-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTJ5LkS0OFch|ryPMYjTRW5ITVJ?
T98GMlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nmeGlEPTB;MkeuOVg1PiEQvF2=MoDiV2FPT0WU
RPMI-8866NHrsbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzuTWM2OD1{Nz63OVYzKM7:TR?=M2\3dnNCVkeHUh?=
BENNXP3PWVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLZTWM2OD1{Nz64OVE4KM7:TR?=NIHqV3JUSU6JRWK=
MDA-MB-231MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTJ6LkK3PVUh|ryPMnzVV2FPT0WU
HuH-7MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLHTWM2OD1{OD60NFI5KM7:TR?=NF;1O2tUSU6JRWK=
SK-N-FINXzrbY1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\pc4ZKSzVyPUK4MlQ{OyEQvF2=NWXUTWlDW0GQR1XS
AN3-CANWDCU25LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJ6LkSzPVUh|ryPNF3YfHpUSU6JRWK=
EGI-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jXemlEPTB;MkiuOVkzQCEQvF2=M1fWcnNCVkeHUh?=
697MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moe2TWM2OD1{OD62N|MyKM7:TR?=NF\S[45USU6JRWK=
TCCSUPNVnxWJhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3zTWM2OD1{OD62OFE5KM7:TR?=M{\jb3NCVkeHUh?=
GR-STM3vSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3yTWM2OD1{OD62Olk3KM7:TR?=Mle3V2FPT0WU
SK-N-DZMmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rYWGlEPTB;MkiuOlg5PSEQvF2=MV3TRW5ITVJ?
MIA-PaCa-2MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTJ6Lke5OVkh|ryPNYi5fnM4W0GQR1XS
IGR-1M1jGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\vTWM2OD1{OD64PFc1KM7:TR?=NX63eVJvW0GQR1XS
BFTC-905NYrXb5ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJ7LkK3NFUh|ryPM{[3SnNCVkeHUh?=
NCI-H1581MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYntZVUzUUN3ME2yPU4{OTR3IN88US=>MXXTRW5ITVJ?
RDNV7TUo1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLjVIdQUUN3ME2yPU42OjN|IN88US=>M4nkNnNCVkeHUh?=
SF268NF;FXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTJ7LkW5N|Eh|ryPNUHvZ2g5W0GQR1XS
SHP-77Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fDbWlEPTB;MkmuOlE5OiEQvF2=MnSxV2FPT0WU
D-566MGMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3z0bGlEPTB;MkmuPVM6OyEQvF2=MWrTRW5ITVJ?
TGBC1TKBNXf6N286T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTNyLkGyN|gh|ryPMX7TRW5ITVJ?
MEL-HONUPnWWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTNyLkG0NlMh|ryPMWnTRW5ITVJ?
SJRH30MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTNyLkKxNFgh|ryPMkXrV2FPT0WU
D-336MGMm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTNyLkK4PVIh|ryPMkHhV2FPT0WU
C3AMoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4joZ2lEPTB;M{CuNlkzPyEQvF2=MWHTRW5ITVJ?
Calu-6M3\EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{e3RmlEPTB;M{CuNlk3OyEQvF2=M1LPbnNCVkeHUh?=
MZ1-PCMkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7LTWM2OD1|MD6zPVMh|ryPNEj0N5JUSU6JRWK=
KYSE-70MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDCXmxNUUN3ME2zNE42OTF2IN88US=>NFuwRYJUSU6JRWK=
CAPAN-1NX\DSHcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2G1O2lEPTB;M{CuOVE5OSEQvF2=M{nre3NCVkeHUh?=
DK-MGMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3vTWM2OD1|MD61OFU3KM7:TR?=NUfLRY5OW0GQR1XS
SK-HEP-1M3\3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi1eIlKSzVyPUOwMlY{OjZizszNM{\kfnNCVkeHUh?=
MS-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLEWZlKSzVyPUOwMlg5QDlizszNM2jUcXNCVkeHUh?=
GI-ME-NNEjVfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvvTWM2OD1|MT6wOVcyKM7:TR?=NYm2XIZ{W0GQR1XS
NCI-H510AMmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTNzLkSwNFYh|ryPMk\jV2FPT0WU
NB17MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrzT4FqUUN3ME2zNU42OTh3IN88US=>MWTTRW5ITVJ?
639-VNGO5flZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXn[|RYUUN3ME2zNU42OjR|IN88US=>NU\nWFA4W0GQR1XS
CAL-51MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4e0XGlEPTB;M{GuOVY3PyEQvF2=MVTTRW5ITVJ?
HGC-27NWP2cW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTNzLkW4O|Mh|ryPMXnTRW5ITVJ?
GOTOM{DRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTNzLki1NFYh|ryPNW\ieXFlW0GQR1XS
ChaGo-K-1NIrQTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXQOWRKSzVyPUOyMlAxPyEQvF2=MojmV2FPT0WU
RO82-W-1NUH1ZnZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTN{LkG2NFQh|ryPMlfXV2FPT0WU
SH-4M1yzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTN{LkG4OVgh|ryPM1:0b3NCVkeHUh?=
A204M3vOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;aTWM2OD1|Mj61NFY6KM7:TR?=MmXPV2FPT0WU
DMS-273NEH3[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUP2e4pkUUN3ME2zNk42OzJ{IN88US=>NYHNU5lYW0GQR1XS
KGNNFnWWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;V[WVPUUN3ME2zNk43OzNizszNM1nkdnNCVkeHUh?=
SK-MEL-2MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M135d2lEPTB;M{KuOlUzPyEQvF2=NIS1eI9USU6JRWK=
NCI-H2228NV;BSXNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEm5dHVKSzVyPUOyMlY3ODJizszNMnv2V2FPT0WU
MKN28MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfub3FKSzVyPUOyMlc5OzhizszNNH3YWGNUSU6JRWK=
H-EMC-SSM13TPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17q[mlEPTB;M{KuPVY4QCEQvF2=NYm4WYhtW0GQR1XS
ATN-1MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVe5OotpUUN3ME2zN{4yPDF4IN88US=>NFPYTmNUSU6JRWK=
D-263MGMo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\Oe|FTUUN3ME2zN{45Ozd6IN88US=>Mn3OV2FPT0WU
LU-135MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3EbWNbUUN3ME2zN{45QDJ7IN88US=>Mn[3V2FPT0WU
C8166NFuzXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rjTmlEPTB;M{OuPFg2PCEQvF2=NIjPc5hUSU6JRWK=
T-24M4PUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTN2LkCyNFUh|ryPM3\pbHNCVkeHUh?=
MewoNVX5dZl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTN2LkGzOFkh|ryPNEjnU3VUSU6JRWK=
22RV1M{C4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTN2LkG3OVQh|ryPMVvTRW5ITVJ?
KM-H2MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkKxTWM2OD1|ND6xO|c6KM7:TR?=MkHBV2FPT0WU
NCI-H2122MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTN2LkO0O|Eh|ryPMVLTRW5ITVJ?
ABC-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLZTWM2OD1|ND6zOlk{KM7:TR?=NXrzW5lCW0GQR1XS
NCI-H1355NXnBcHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnf4TWM2OD1|ND6zPFg6KM7:TR?=M3yx[nNCVkeHUh?=
NOMO-1NWTOPHhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHiyNHdKSzVyPUO0MlU4ODNizszNNE[4[4tUSU6JRWK=
MZ7-melMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXW4XmV3UUN3ME2zOE43PDh5IN88US=>NWrOWIprW0GQR1XS
NCI-H810NIrW[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjjZ5NKSzVyPUO0MlczPzhizszNNGnHVoJUSU6JRWK=
D-392MGM1fqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnENWpsUUN3ME2zOU4xPTZ3IN88US=>MYjTRW5ITVJ?
LB771-HNCNEnHPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlS2TWM2OD1|NT6xOlU5KM7:TR?=NV;h[|ZjW0GQR1XS
COLO-679MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnOwTWM2OD1|NT6zPFgh|ryPNEi3WZNUSU6JRWK=
SK-PN-DWNV3ENoJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TLRWlEPTB;M{WuOFM3QSEQvF2=MmXSV2FPT0WU
VA-ES-BJNXzC[mxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTN3LkS2OFkh|ryPMn7VV2FPT0WU
KNS-42NF7rPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrwXndKSzVyPUO1MlU5OjZizszNNIPVN2hUSU6JRWK=
RVH-421NInE[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\HTWM2OD1|NT63OlQ2KM7:TR?=NES1TItUSU6JRWK=
P30-OHKMlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zEZ2lEPTB;M{WuPFc2OiEQvF2=MoHOV2FPT0WU
G-402M2rwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTN3Lkm4Olch|ryPNFz3N2hUSU6JRWK=
S-117NX3W[|J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NITVW3hKSzVyPUO2MlMxODhizszNM2rpb3NCVkeHUh?=
RXF393NXOyUmdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPBVYJKSzVyPUO2MlM4QDVizszNNEXxdpNUSU6JRWK=
LCLC-103HNWnNR|BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTN4Lke4NFMh|ryPMmi0V2FPT0WU
U-118-MGNWf3UFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17PeGlEPTB;M{[uPFg1PyEQvF2=Ml7qV2FPT0WU
8-MG-BAMnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTSTWM2OD1|Nj65OFg{KM7:TR?=NYLTb5czW0GQR1XS
MFH-inoNG\sZ|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPJTWM2OD1|Nz6zN|cyKM7:TR?=NUDNZo5[W0GQR1XS
NCI-H23NFLhbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnzMTWM2OD1|Nz60NVk3KM7:TR?=M3XO[nNCVkeHUh?=
NCI-H446NET6VXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LIemlEPTB;M{euOFg3OiEQvF2=NGOyU4xUSU6JRWK=
LU-99AM2fPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjvc5dMUUN3ME2zO{42PzNzIN88US=>MmjDV2FPT0WU
KP-N-YNNWDuSFRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn60TWM2OD1|Nz62NVk2KM7:TR?=NIDQOGVUSU6JRWK=
SCC-9MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLTTWM2OD1|Nz63PFM5KM7:TR?=NGnoenFUSU6JRWK=
EFM-19NX;Lflg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jRcWlEPTB;M{euO|k3PyEQvF2=NVv6S25JW0GQR1XS
A427MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfrTWM2OD1|Nz65NVA4KM7:TR?=MYTTRW5ITVJ?
LB831-BLCNFfwfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nTOGlEPTB;M{iuOlA{QSEQvF2=NGDjcXFUSU6JRWK=
HOSMmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTOO2t2UUN3ME2zPU43Ojd|IN88US=>NF\XNIhUSU6JRWK=
LAN-6Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jKOGlEPTB;NECuNFEyOiEQvF2=NWjOfmVrW0GQR1XS
U251NXXJW2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXr5OWZVUUN3ME20NE41ODV2IN88US=>M3Ln[HNCVkeHUh?=
SNU-387NWnTZlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIq4ZndKSzVyPUSwMlQ2PTNizszNMYnTRW5ITVJ?
DMS-79NY\ieng{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTRyLkW4PFkh|ryPMoPDV2FPT0WU
SK-LU-1Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzzbG91UUN3ME20NE43PTZ6IN88US=>NWSweXZkW0GQR1XS
HTNHLIc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrhTWM2OD12MD62OlM6KM7:TR?=MmfVV2FPT0WU
KP-N-YSMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPaSFFnUUN3ME20NE43PzZ6IN88US=>NH25W|JUSU6JRWK=
DMS-114M2Py[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\HblFKSzVyPUSwMlg{PzRizszNNUjxZ5pJW0GQR1XS
HUTU-80NVTpRWJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2faU2lEPTB;NEGuNFU3QSEQvF2=MVzTRW5ITVJ?
ONS-76NH[2c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn;iTWM2OD12MT60O|A6KM7:TR?=NYKxdplZW0GQR1XS
A673MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDkR41KSzVyPUSxMlUyPTdizszNNXzRfVdJW0GQR1XS
HPAF-IINUTQfYxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPKcYNUUUN3ME20NU43PzB7IN88US=>MmLjV2FPT0WU
UACC-257NV;mNFNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnBTWM2OD12MT63N|Y6KM7:TR?=NYPOe285W0GQR1XS
EW-22NIXQVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonXTWM2OD12MT64Olk4KM7:TR?=MXTTRW5ITVJ?
NCI-H1755NULz[mRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXB[41LUUN3ME20NU45PzJ3IN88US=>NWrHXIsxW0GQR1XS
KYSE-150NEDRT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTR{LkG3PFIh|ryPMlHNV2FPT0WU
CGTH-W-1NFjUU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELP[VlKSzVyPUSyMlQ6PTVizszNNHfaeXJUSU6JRWK=
NB13M3vQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTR{Lk[yNVch|ryPMnrSV2FPT0WU
SW872M2HSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTR{Lk[zN|Eh|ryPMVHTRW5ITVJ?
KP-4NFrrRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnET5hFUUN3ME20Nk45QDN{IN88US=>MlzzV2FPT0WU
HCC38NEflWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnX2TWM2OD12Mj65OlE5KM7:TR?=MX;TRW5ITVJ?
BB49-HNCM3X0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPlb2xKSzVyPUSzMlI{PTZizszNNGCxVVhUSU6JRWK=
CAL-62M{fJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInqcYtKSzVyPUSzMlQxOjhizszNMV3TRW5ITVJ?
NCI-H2029MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrScFhKSzVyPUSzMlU2QDFizszNM{L0[nNCVkeHUh?=
M14NVfvbIRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTR2LkGzN|Ih|ryPNVP5c5d5W0GQR1XS
COLO-680NM3\tcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDIUlhKSzVyPUS0MlM{QSEQvF2=NEDTU4pUSU6JRWK=
Hs-578-TM3\T[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3SxdWlEPTB;NEWuNFI6PCEQvF2=NUTQeZI2W0GQR1XS
MSTO-211HNUX1e2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{f6bmlEPTB;NEWuPVQ5OiEQvF2=M1zRN3NCVkeHUh?=
EW-1Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTR3Lkm2PFkh|ryPMXHTRW5ITVJ?
SW948MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\hV5RKSzVyPUS2MlQ1PjJizszNM3fKVnNCVkeHUh?=
NCI-H460M3SyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrESWhwUUN3ME20Ok42OjNizszNMYnTRW5ITVJ?
CAS-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTR4Lke3NFEh|ryPNHTUOphUSU6JRWK=
TGBC11TKBNYewXo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrnfG9KSzVyPUS3MlE4PzdizszNM2PBUHNCVkeHUh?=
HD-MY-ZNWXqN|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjVTWM2OD12OD63PFYh|ryPNHnZOHNUSU6JRWK=
NCI-H226NYHkdGtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIe1OlZKSzVyPUS5Mlc4QDVizszNNVr0R5NMW0GQR1XS
PA-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfkSW9KSzVyPUS5Mlg{OzVizszNMWHTRW5ITVJ?
LB2518-MELM2XEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTR7Lki3NlMh|ryPNWPCSmZlW0GQR1XS
A101DMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HOT2lEPTB;NEmuPVQzPSEQvF2=MWrTRW5ITVJ?
NCI-H2087NIPnfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGG5WnBKSzVyPUS5Mlk3QDJizszNMkmyV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. [1]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

In vitro kinase activity assays The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.

Cell Assay:

[1]

Cell lines NSCLC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

1 × 104 NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 104 cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm.

Animal Study:

[1]

Animal Models Athymic NMRI-nu/nu female mice
Formulation In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80)
Dosages 20 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Li D, et al. Oncogene, 2008, 27(34), 4702-4711.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02795156 Not yet recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boe  ...more SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer July 2016 Phase 2
NCT02780687 Not yet recruiting Urologic Neoplasms Boehringer Ingelheim June 2016 Phase 2
NCT02183883 Not yet recruiting Non-small Cell Lung Cancer University College, London|Boehringer Ingelheim May 2016 Phase 2
NCT02716311 Not yet recruiting Non Small Cell Lung Cancer Intergroupe Francophone de Cancerologie Thoracique April 2016 Phase 2
NCT02501603 Not yet recruiting Gastric Cancer|Gastroesophageal Junction Cancer Yonsei University March 2016 Phase 2

view more

Chemical Information

Download Afatinib (BIBW2992) SDF
Molecular Weight (MW) 485.94
Formula

C24H25ClFN5O3

CAS No. 439081-18-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 97 mg/mL (199.61 mM)
Ethanol 15 mg/mL (30.86 mM)
Water <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose+0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

Customer Product Validation(3)


Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method CEER assay
Cell Lines H460/A549/RFU cell lines
Concentrations 0-10 μM
Incubation Time 4 h
Results This data showed that a potent dose-dependent inhibition of the HER1 and HER2 pathways in the HCC827 cells was observed by treatment with BIBW-2992. Other HER1 and/or HER2 pathway-activated cell lines, H1975 and H1650, were likewise had these pathway activations blocked by the treatment with BIBW-2992.

Click to enlarge
Rating
Source Int J Proteomics 2011 2011, 215496. Afatinib (BIBW2992) purchased from Selleck
Method Nikon inverted-phase microscope
Cell Lines lung tumor cell lines
Concentrations 0.1/1 µM
Incubation Time two weeks
Results Reduction of cell colony size formation was observed by the treatment with the irreversible HER1/2 inhibitor BIBW-2992 in H1975 and H1650 cells as seen when these cells were grown in an anchorage-dependent manner.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Afatinib (BIBW2992) purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 3 h
Results BIBW2992 treatment resulted in a reduction of EGFR phosphorylation in Breast cancer cells.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related EGFR Products

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Afatinib (BIBW2992) Dimaleate

    Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.

  • Poziotinib (HM781-36B)

    Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

  • Erlotinib HCl (OSI-744)

    Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • Osimertinib (AZD9291)

    Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

  • Lapatinib

    Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

  • AG-490 (Tyrphostin B42)

    AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

  • Rociletinib (CO-1686, AVL-301)

    Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

  • AG-1478 (Tyrphostin AG-1478)

    AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Recently Viewed Items

Tags: buy Afatinib (BIBW2992) | Afatinib (BIBW2992) ic50 | Afatinib (BIBW2992) price | Afatinib (BIBW2992) cost | Afatinib (BIBW2992) solubility dmso | Afatinib (BIBW2992) purchase | Afatinib (BIBW2992) manufacturer | Afatinib (BIBW2992) research buy | Afatinib (BIBW2992) order | Afatinib (BIBW2992) mouse | Afatinib (BIBW2992) chemical structure | Afatinib (BIBW2992) mw | Afatinib (BIBW2992) molecular weight | Afatinib (BIBW2992) datasheet | Afatinib (BIBW2992) supplier | Afatinib (BIBW2992) in vitro | Afatinib (BIBW2992) cell line | Afatinib (BIBW2992) concentration | Afatinib (BIBW2992) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us